WVP
FOMX

Worth Venture Partners’s Foamix Pharmaceuticals Ltd. Ordinary Shares FOMX Stock Holding History

Worth Venture Partners’s Portfolio FOMX Stock Details FOMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-9,800
Closed -$51K – 169
2017
Q1 		$51K Buy
+9,800
New +$94.3K 0.05% 110

Other funds holding FOMX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

Worth Venture Partners's FOMX Position: Q4 2019 in Review

Worth Venture Partners sold out of Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) in Q4 2019, closing a stake of 23,627 shares — an estimated $72K sold.

Worth Venture Partners first reported a position in FOMX in Q1 2017 and held it in 5 quarters. The position peaked at $72K in Q3 2019. 65 funds tracked by Wall St. Rank hold FOMX as of Q4 2019.

  • Worth Venture Partners reported no remaining Foamix Pharmaceuticals Ltd. Ordinary Shares position as of Q4 2019 after selling out during the quarter.
  • Worth Venture Partners sold 23,627 Foamix Pharmaceuticals Ltd. Ordinary Shares shares in Q4 2019, an estimated $72K.
  • Worth Venture Partners first reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares in Q1 2017 and held it in 5 quarters.
  • Worth Venture Partners's Foamix Pharmaceuticals Ltd. Ordinary Shares position peaked at $72K in Q3 2019.
  • 65 funds tracked by Wall St. Rank held Foamix Pharmaceuticals Ltd. Ordinary Shares as of Q4 2019.

Based on Worth Venture Partners's 13F filing for Q4 2019, filed 14 Feb 2020.